Reports from University of Tokyo Highlight Recent Findings in Osteoporosis (Adherence To Daily, Weekly, and Monthly Dosing Regimens of Bisphosphonates for Osteoporosis Treatment In Postmenopausal Women In Japan: a Retrospective Study Using …): Musculoskeletal Diseases and Conditions – Osteoporosis

2021 DEC 21 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- Data detailed on Musculoskeletal Diseases and Conditions - Osteoporosis have been presented. According to news reporting originating in Tokyo, Japan, by NewsRx journalists, research stated, “Poor medication adherence of osteoporosis patients is a major global medical problem because of its negative impact on health outcomes and quality of life. The aim of this study was to evaluate how differences in dosing regimens influence adherence to oral bisphosphonates using data from a large health insurance provider in Japan.”

Funders for this research include Grants-in-Aid for Scientific Research (KAKENHI), NEC Corporation.

The news reporters obtained a quote from the research from the University of Tokyo, “This was a retrospective observational study using claims data obtained between October 2012 and January 2018, from the community-based National Health Insurance program of a large city in Japan. The data included in the analysis were obtained from women 60 to 74 years old whose oral bisphosphonate prescription was detected between April 2013 and February 2017. Treatment adherence was monitored from the initial prescription for one year, i.e., up to January 2018. Primary comparisons among the daily-dosing, weekly-dosing, and monthly-dosing groups were based on the mean medication possession ratio (MPR). Data from a total of 3,958 patients were analyzed. The numbers of patients aged 60-64, 65-69, and 70-74 were 425, 1,400, and 2,133, respectively. The highest mean MPR was 69.4% for the monthly-dosing of bisphosphonates, followed by the weekly-dosing at 63.5%, and daily-dosing at 57.2%. Using the Kruskal-Wallis test with Dunn-Bonferroni correction, there were significant differences in mean MPR for daily versus weekly (p < 0.01), daily versus monthly (p < 0.001), and weekly versus monthly dosing regimens (p < 0.05).”

According to the news reporters, the research concluded: “These results suggest significantly more patients adhere to a monthly or weekly regimen of bisphosphonates in the treatment of osteoporosis than to a daily regimen.”

This research has been peer-reviewed.

For more information on this research see: Adherence To Daily, Weekly, and Monthly Dosing Regimens of Bisphosphonates for Osteoporosis Treatment In Postmenopausal Women In Japan: a Retrospective Study Using Claims Data. The Tohoku Journal of Experimental Medicine, 2021;255(2):147-155. The Tohoku Journal of Experimental Medicine can be contacted at: Tohoku Univ Medical Press, 2-1, Seiryo-Machi, Aoba-Ku, Sendai, Miyagi 980-8575, Japan.

Our news correspondents report that additional information may be obtained by contacting Yasuki Kobayashi, University of Tokyo, Graduate School of Medicine, Dept. of Public Health, Tokyo, Japan. Additional authors for this research include Yuki Kosaka, Takehiro Sugiyama and Konan Hara.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1620/tjem.255.147. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)